A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma by Burton, C et al.
A phase III trial comparing CHOP to PMitCEBO with or without
G-CSF in patients aged 60 plus with aggressive non-Hodgkin’s
lymphoma
C Burton
1, D Linch
1, P Hoskin
2, D Milligan
3, MJS Dyer
4, B Hancock
5, P Mouncey
1, P Smith
1, W Qian
6,
K MacLennan
7, A Jack
7, A Webb
8 and D Cunningham*,8
1University College London and CRUK Clinical Trials Centre, 222 Euston Road, London NW1 2DA, UK;
2Mount Vernon Hospital, Rickmansworth Road,
Northwood HA6 2RN, UK;
3Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK;
4University of Leicester, Lancaster Road,
Leicester LE1 9HN, UK;
5Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK;
6MRC Clinical Trials Centre, 222 Euston Road, London NW1
2DA, UK;
7Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK;
8Department of Oncology, Royal Marsden Hospital, Downs Road, Sutton,
Surrey SM2 5PT, UK
The management of older patients with aggressive non-Hodgkin’s lymphoma presents a challenge to the physician. Age is a poor
prognostic indicator, due to reduced ability to tolerate and maintain dose-intensive chemotherapy. Generally, older patients
demonstrate a lower response rate, reduced survival and increased toxicity, although the majority of large randomised trials exclude
older patients. This randomised trial was conducted in patients 60 years or over to compare CHOP (cyclophosphamide 750mgm
 2,
doxorubicin 50mgm
 2, vincristine 1.4mgm
 2, prednisolone 100mg) with PMitCEBO (mitoxantrone 7mgm
 2, cyclophosphamide
300mgm
 2, etoposide 150mgm
 2, vincristine 1.4mgm
 2, bleomycin 10mgm
 2 and prednisolone 50mg). Due to the
myelosuppressive nature of these regimens, patients were also randomised to the addition of G-CSF. The formal results of this trial
with long-term follow-up are now reported. Data were analysed to assess efficacy and toxicity. Overall response rate was 84% in the
CHOP arm and 83% in the PMitCEBO arm, with overall response rates of 83% for the use of G-CSF and 84% for no G-CSF. At
median 44 months follow-up, there was no significant difference in failure-free, progression-free or overall survival between the
CHOP and PMitCEBO arms. At 3 years, the actuarial failure-free survival was 44% in CHOP recipients and 42% in PMitCEBO
recipients and the 3-year actuarial overall survival was 46% and 45% respectively. There was no significant difference in the failure-
free, progression-free or overall survival with the addition of G-CSF.
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The reported incidence of aggressive non-Hodgkin’s lymphomas
(NHL) has doubled in recent decades, and this increase has been
predominantly observed in older patients (McNally et al, 1999;
2001 Census; Muller et al, 2005). Advanced age is an independent
poor prognostic factor, with inability to tolerate chemotherapy and
maintain dose intensity (International NHL Prognostic Factors
Project, 1993; NHL Classification Project, 1997; Bastion et al,
1997). Higher treatment-related mortality has also been reported
in older patients using the CHOP (cyclophosphamide, doxorubicin,
vincristine and prednisolone) regimen (Armitage and Potter,
1984). For these reasons, specific regimens have been developed
for treating elderly patients, involving dosage reductions and
shortening of the period of treatment (Meyer et al, 1995; Sonneveld
et al, 1995). These curtailed regimens have tended to result in a
lower toxic death rate but also a lower complete response (CR)
rate.
The British National Lymphoma Investigation (BNLI) group
have had considerable experience with the 12 weekly PACEBOM
regimen (prednisolone, adriamycin, cyclophosphamide, etoposide,
bleomycin, vincristine, methotrexate), which alternates myelo-
suppressive and non-myelosuppressive agents (Sweetenham et al,
1991). In a randomised trial in patients under the age of 70 years,
PACEBOM was shown to be as efficacious as CHOP (Linch et al,
2000). One potential advantage of the PACEBOM regimen is the
lower planned total dose of anthracycline (30% reduction), which
might be particularly relevant to the older patient. Several recent
studies have shown that anthracycline-related cardiotoxicity is
more frequent in older patients (Limat et al, 2003; Swain et al,
2003). Swain et al suggested that the threshold for cardiac damage
is doxorubicin 400mgm
 2. Limat et al suggested it is even lower.
The tolerability of PACEBOM in the older population though was
frequently limited by mucositis, and subsequently the metho-
trexate was omitted. This PACEBO regimen was then compared in
a randomised trial, in elderly patients with histologically aggressive
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sNHL, with PMitCEBO, in which the 35mgm
 2 adriamycin was
replaced by 7mgm
 2 mitoxantrone, an anthracenedione deriva-
tive (Mainwaring et al, 2001). This trial suggested that PMitCEBO
was superior to PACEBO, with an encouraging 40% survival at 4
years. This contrasts with the findings in another trial where the
substitution of adriamycin by mitoxantrone had a negative impact
(Sonneveld et al, 1995). In the trial reported here, PMitCEBO has
been compared with standard CHOP.
Both the PMitCEBO and CHOP regimens result in considerable
myelosuppression in the elderly population and the value of using
granulocyte colony-stimulating factor (G-CSF) to mitigate against
the chemotherapy induced neutropenia was also explored.
Previous studies in lymphoma have suggested that the use of G-
CSF results in less granulocyte suppression, less infection and
hospitalisation, possibly allowing a higher dose intensity with
improved response rates and with significant economic benefits
(Pettengell et al, 1992; Gerhartz et al, 1993; Bertini et al, 1994;
Zagonel et al, 1994; Niitsu and Umeda, 1995; Silvestri et al, 1995).
Few previous studies have been adequately powered, however, to
evaluate the impact of G-CSF use on survival. In the trial reported
here, the use of G-CSF in combination with chemotherapy has
been compared with chemotherapy alone.
The mature results of this study of 784 patients are presented in
this paper.
PATIENTS AND METHODS
Patient selection
Patients were eligible if aged 60 years or over with previously
untreated, bulky stage IA or stages IB-IV aggressive NHL. There
was no upper age limit. Between 1997 and 1999 patients with a
histological diagnosis of diffuse mixed cell, diffuse large cell or
diffuse immunoblastic lymphoma according to the Working
Formulation were included. From 2000 the histological diagnosis
was made according to the World Health Organisation and
patients with diffuse large B-cell lymphoma were included. Central
review including immunophenotyping was performed at a later
date in 627 cases and in 52 (8%) the patient was considered
ineligible on histological criteria either because of a change in
diagnosis or because of inadequate material. The analyses
performed were on an intention to treat basis and patients were
not excluded after randomisation.
Full clinical staging with routine haematological and biochem-
ical blood tests, computed tomography (CT) imaging of the chest,
abdomen and pelvis and bone marrow biopsy were performed.
Any patient with central nervous system disease, lymphoblastic or
Burkitt lymphoma was excluded from the trial. Patients with
significant renal, hepatic or cardiac dysfunction were excluded
(creatinine4150mmoll
 1, bilirubin435mmoll
 1, left ventricular
ejection fractiono50%, respectively). No patients with medical
conditions, other than aggressive non-Hodgkin’s lymphoma,
prohibiting intensive therapy were included and no patient had
received systemic treatment for cancer in the preceding 5 years.
Trial design
Between October 1997 and September 2003, 784 newly diagnosed
patients from 92 centres in UK were entered into the trial. The trial
had a 2 2 factorial design; randomisations between CHOP and
PMitCEBO (comparing all patients randomised to CHOP with all
patients randomised to PMitCEBO) and the addition or not of G-
CSF (comparing all patients randomised to G-CSF with all those
patients not randomised to G-CSF).
The CHOP regimen was given 3-weekly for a maximum of eight
cycles and the PMitCEBO regimen weekly for a maximum of 16
weeks (Table 1). Prophylactic G-CSF (Lenograstim) 263mgday
 1
was administered if randomised to G-CSF from days 8 to 14 in the
CHOP arm and days 6 to 12 in the PMitCEBO arm. All patients
received allopurinol for weeks 1–3 and co-trimoxazole prophy-
laxis week 1 to treatment end plus 2 weeks. Patients treated with
CHOP chemotherapy were assessed clinically and by CT imaging
after 2, 4 and 6 cycles. If CR or non-progressive partial remission
(PR) was achieved, patients were treated with six cycles of CHOP.
If in a progressive PR at six cycles, two further cycles of CHOP
were given. For patients treated with PMitCEBO, initial response
was assessed clinically and by CT imaging after 4, 8 and, if
applicable, 12 weeks. Patients were treated to CR or nonprogres-
sive PR, plus a further 4 weeks of chemotherapy. Methotrexate
12.5mg intrathecally was given as six doses at weekly intervals to
patients with peripheral blood, orbital, testicular or facial sinus
disease.
Dose reduction was identical for both chemotherapy regimens
and based on Southwest Oncology Group studies (Fisher et al,
1993). No dose modifications were made on the first cycle based on
blood counts. Dose modifications for haematological toxicity for
subsequent cycles were made as presented in Table 2. No dosage
reduction was made for low haemoglobin. Blood transfusions were
given to maintain haemoglobin 410gdl
 1. The dose of anthra-
cycline was also reduced by 50 or 75% if the serum bilirubin was
raised to 35–50 or 450mmoll
 1, respectively. Bleomycin was
discontinued if there were any clinical signs or radiological
evidence of pulmonary infiltration/fibrosis developing. Bleomycin
was also discontinued if severe skin toxicity developed. Vincristine
was reduced by 50% in patients with grade 2 motor toxicity (mild,
objective weakness, but no significant impairment of function) and
Table 1 Treatment regimens for CHOP and PMitCEBO
CHOP PMitCEBO
Cyclophosphamide 750mgm
 2 day 1 Cyclophosphamide 300mgm
 2 day 1
Doxorubicin 50mgm
 2 day 1 Mitoxantrone 7mgm
 2 day 1
Vincristine 1.4mgm
 2 day 1 Etoposide 150mgm
 2 day 1
Prednisolone 100mg daily days 1–5 Prednisolone 50mg daily weeks 1–4,
50mg alternate days week 5 to
treatment end
Vincristine 1.4mgm
 2 day 8
Bleomycin 10mgm
 2 day 8
Table 2 Dose modifications due to haematological toxicity, cycle 2 onwards
Platelet count 10
9l
 1 Neutrophil count 10
9l
 1 Dose adjustment for CHOP Dose adjustment for PMitCEBO
100+ 41.5 100% 100%
75–99 1.0 75% cyclophosphamide, doxorubicin 100%
50–74 0.5–1.0 50% cyclophosphamide, doxorubicin 65% cyclophosphamide, mitoxantrone, etoposide
100% vincristine 100% vincristine, bleomycin
o50 o0.5 Delay all drugs for 1 week Delay all drugs for 1 week
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sgrade 3 sensory toxicity (severe objective sensory loss or
paraesthesiae interfering with function). Vincristine was comple-
tely omitted for higher grades of toxicity.
Response assessment
Computed tomography imaging was used to assess response as in
Table 3. This was repeated 1 and 3 months after completion of
chemotherapy. Further clinical assessment continued 3-monthly
for the first year, 6-monthly for 5 years and annually thereafter.
Symptoms relating to cardiac status were elicited on each occasion.
Statistical considerations
This trial had a 2 2 factorial design and the primary end point
for both randomisations was failure-free survival (FFS) defined as
the time from the date of randomisation to the date of progression
or death from disease, including non-responders, or death from
treatment toxicity. Secondary end points for the comparison of
CHOP with PMitCEBO and for the addition of G-CSF were
response rates, toxicity, progression-free survival (PFS) and overall
survival (OS). Progression-free survival was calculated from the
date of randomisation to the date of progression or death from any
cause whichever occurred first. Duration of OS was calculated from
the date of randomisation to the date of death from any cause. At
the time of the analysis, survivors were censored at the date they
were last known to be alive. The log-rank test was applied to
compare the Kaplan–Meier curves for FFS, PFS and OS (Kaplan
and Meier, 1958). The standard w
2 test for frequency was used to
compare response rate (CR) of treatment. Additional secondary
end points for the G-CSF intervention were the number of in-
patient days with and without sepsis.
The trial was powered to detect a 10% difference in the primary
end point of FFS (assuming that the 3 year FFS with CHOP alone
would be 30%), with a power of 90% and a significance level of 5%
in a two-sided log-rank test for each of the two variables. Thus, the
calculated sample size was 880 patients (440 in each arm). All
analyses were on an intention to treat basis.
RESULTS
Over 6 years, 784 eligible patients were entered into the trial. It was
then closed prematurely following guidance from the UK National
Institute for Clinical Excellence (NICE) that Rituximab should be
given in combination with chemotherapy in all patients with
diffuse large B-cell lymphoma. The median age of patients entered
was 70 years (range 60–89). There were 411 (52%) male and 373
(48%) female patients. The proportion of patients with age
adjusted international prognostic index risk (IPI) scores of 0, 1,
2, 3 was 16, 30, 37 and 17%, respectively. Over half the patients
thus had poor prognostic disease.
Of these eligible patients, 195 patients were randomised into the
CHOP arm, 202 into the PMitCEBO arm, 192 into the CHOPþG-
CSF arm, and 195 into the PMitCEBOþG-CSF arm. The four
cohorts were well balanced for all clinical characteristics (Table 4).
Histological subtypes were well matched between the four cohorts.
T-cell immunophenotype was seen in eleven cases in the CHOP
arm, six cases in the PMitCEBO arm, seven cases in the CHOPþG-
CSF arm and nine cases in the PMitCEBOþG-CSF arm. Analysis
of the primary end point of FFS, revealed no significant interaction
between the two randomisations (P¼0.22) and the trial has
therefore been analysed in accordance with the 2 2 factorial
design, comparing the two CHOP cohorts with the two PMitCEBO
cohorts and the two regimens with and without G-CSF. Data on the
individual four treatment arms are only shown for reasons of
exploratory or clinical information.
Of the CHOP recipients, 25% of patients received less than six
cycles of chemotherapy predominantly due to early treatment
failure. In total, 59% of patients received six cycles and 16%
received more than this. In the PMitCEBO arm, 15% received less
than eight cycles, 65% received 8–12 cycles, and 19% received
13–16 cycles. Of the patients randomised to receive G-CSF, it was
given in 99% and of those randomised not to receive G-CSF, it was
given in 8%; 17 patients in the CHOP arm and 12 patients in the
PMitCEBO arm. In the majority of cases, G-CSF was given to
maintain dose intensity due to haematological toxicity (fourteen
patients) or as secondary prophylaxis (four patients). This was
mainly initiated between courses 2 and 4. In the remaining cases,
G-CSF was given due to a transcription error or the reason was not
known. The use of radiation therapy was not stipulated in the
protocol. Generally, involved field radiotherapy was given at the
Table 3 Criteria for response assessment
Response Definition
CR Resolution of all clinical and radiological abnormalities
detected at presentation
PR 450% resolution of all disease determined by product
of two diameters
Non-progressive PR No further reduction in previously responding disease
Progressive PR Further reduction in previously responding disease
Nonresponse o50% response subdivided into: (i) progressive disease
if 450% increase in disease volume or development of
new lesions; (ii)stable disease if disease status
insufficient to meet criteria of partial response or
progressive disease
Table 4 Patient characteristics
CHOP PMitCEBO
CHOP+
GCSF
PMitCEBO+
GCSF Total
Age (years)
Median 70 70 71 71 70
Range 60–86 60–89 60–87 60–85 60–89
Sex (%)
Female 46 48 48 48 48
Male 54 52 52 52 52
Stage (%)
I9 8 1 1 1 0 1 0
II 29 30 24 23 27
III 29 25 29 34 29
IV 32 36 35 33 34
B Symptoms (%)
A4 9 4 3 5 0 4 2 4 6
B5 1 5 7 5 0 5 8 5 4
WHO PS (%)
03 2 3 1 3 4 3 0 3 2
14 1 4 3 3 7 3 8 4 0
21 7 1 8 2 0 2 6 2 0
38 6 6 4 6
42 2 2 3 2
LDH (%)
Not raised 39 43 34 36 38
Raised 61 57 66 64 62
IPI (%)
01 8 2 0 1 6 1 1 1 6
13 0 3 0 2 8 3 3 3 0
23 9 3 4 3 7 3 7 3 7
31 3 1 6 1 9 1 8 1 7
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send of treatment to sites of initial bulk or residual disease. This
was administered to 40 patients (10%) in the CHOP arm and 41
patients (10%) in the PMitCEBO arm.
Response rates
The overall response rates for CHOP and PMitCEBO were almost
identical at 84 and 83%, respectively (P¼0.69), but the CR rate
with CHOP (55%) was significantly higher than with PMitCEBO
(47%, P¼0.035).
The use of G-CSF had no impact on response rates with an
overall response rate of 83% for the use of G-CSF and 84% for
no G-CSF (P¼0.84). The CR rates of 52% with G-CSF and 50%
without G-CSF were similar (P¼0.45).
Survival
At a median follow-up of 44 months, there was no significant
difference in FFS between CHOP and PMitCEBO (P¼0.76). At 3
years, the actuarial FFS was 44% in CHOP recipients and 42% in
PMitCEBO recipients (Figure 1B). There was also no significant
difference in PFS (P¼0.77) or OS (P¼0.57) (Figure 2B). The
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CHOP N= 387
387 207 134 88 56 27 5
397 202 134 82 52 26 4
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387 207 134 88 56 27 5
397 202 134 82 52 26 4
2
1 = 0.1
2
1 = 2.9
P = 0.76
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G-CSF N= 387
387 205 138 85 55 26 4
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Figure 1 (A–C) Failure-free survival curves. (A) Failure-free survival all
4 arms; (B) failure-free survival CHOP vs PMitCEBO; (C) failure-free
survival G-CSF vs no G-CSF.
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CHOP N= 387
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397 239 155 98 63 31 5
PMitCEBO N= 397
387 243 151 105 66 35 5
397 239 155 98 63 31 5
G-CSF N= 387
387 239 154 102 62 29 4
397 243 152 101 67 37 6
No G-CSF N= 397
387 239 154 102 62 29 4
397 243 152 101 67 37 6
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C
Figure 2 (A–C) Overall survival curves. (A) Overall survival all 4 arms; (B)
overall survival CHOP vs PMitCEBO; (C) overall survival G-CSF vs no G-CSF.
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s3-year actuarial OS for patients receiving CHOP was 46% and for
those receiving PMitCEBO was 45%. In total, 419 patients in this
trial (53%) have died. In total, 318 were due to NHL, 158 in the
CHOP arms and 160 in the PMitCEBO arms.
There was no significant difference in the FFS between those
patients who received G-CSF and those who did not (P¼0.23)
(Figure 1C). Similarly, there was no significant difference in PFS
(P¼0.19) or OS (P¼0.37) (Figure 2C). Of the deaths due to NHL,
there were 147 among patients randomised to receive G-CSF and
171 among those who were not.
Subgroup analysis was performed for all patients according to
IPI scores and age. Patients with IPI score 0 and 1 were compared
with patients with an IPI score of 2 and 3 and patients o70 years
were compared with patients X70 years. The analysis was
performed for CHOP vs PMitCEBO and G-CSF vs no G-CSF.
Patients X70 years had a reduced FFS and OS compared to
patients of o70 years, but there were no significant differences
between any randomised arms for either age cohort (Table 5). The
poor prognosis patients also had a significantly reduced 3-year FFS
and OS but no difference was apparent between randomisations
(Table 5).
Toxicity
The occurrence of grade 3 and 4 haematological toxicity was
significantly more frequent in the PMitCEBO arm (63% of
patients) compared with the CHOP arm (42%) (Po0.0001)
(Table 6). This was mainly due to the increased incidence of
leucopenia in the PMitCEBO arm (60%) compared to CHOP (39%)
(Po0.0001) (Table 7). There was no increase in the maximum
grade of infection toxicity reported with PMitCEBO (P¼0.18) but
these data must be treated with caution, as data on infection rates
were incomplete. Hospitalisation rates and the number of days in
hospital were comparable between CHOP and PMitCEBO (P¼0.3)
(Table 8). Gastrointestinal toxicity was significantly increased in
the CHOP arm (P¼0.008), especially nausea and vomiting
(P¼0.013). Alopecia was also more common in the CHOP arm,
69% of patients developing alopecia in the CHOP arm compared
with 57% in the PMitCEBO arm (P¼0.002). Grade 2–4 neuro-
pathy was increased in the PMitCEBO arm (P¼0.035). Acute and
chronic cardiac toxicity were comparable between both chemo-
therapy regimens. No formal testing of cardiac function was
performed prior to commencing treatment. It is acknowledged that
further chronic cardiac toxicity may become apparent during
prolonged follow-up. There have been 36 cardiac deaths, 17 in the
CHOP arm, and 19 in the PMitCEBO arm (Table 9).
The addition of G-CSF significantly reduced the incidence
of grade 3 and 4 haematological toxicity (P¼0.024) due to a
reduction in grade 3 and 4 leucopenia (P¼0.001) (Tables 6 and 7).
There was also a beneficial effect on the incidence of grade 3 and 4
anaemia associated with the use of G-CSF (P¼0.004). The addition
of G-CSF did not appear to impact on the maximum grade of
infection toxicity (P¼0.71), nor did it influence the hospitalisation
rate or number of days in hospital (P¼0.41) (Table 8). Almost all
time spent in hospital was related to sepsis. An exploratory
Table 5 3 year failure-free and overall survival according to age and IPI
score
CHOP PMitCEBO GCSF No GCSF
3 year failure-free survival
Age (years) % % % %
o70 48 47 50 45
X70 40 38 42 36
IPI score
0–1 56 57 56 55
2–3 36 24 34 26
3-year overall survival
Age years % % % %
o70 53 52 54 51
X70 39 38 41 36
IPI score
0–1 61 61 63 58
2–3 37 29 34 33
Table 6 Maximum grade of haematological toxicity
CHOP
(n¼169)
PMitCEBO
(n¼172)
CHOP+GCSF
(n¼174)
PMitCEBO
+GCSF
(n¼170)
Total
(n¼685)
%% % % %
Haematological toxicity
01 4 1 1 1 5 8
1 22 7 24 19 18
22 1 2 1 2 4 2 1 2 2
31 8 4 0 1 8 2 6 2 5
42 4 3 1 2 4 2 8 2 7
Definitions of haematological toxicity
Grade WBC (10
9l
 1)P o (10
9l
 1)H b ( g d l
 1)
0 X4.0 Within normal limits Within normal limits
1 3.0–3.9 75.0-normal 10.0-normal
2 2.0–2.9 50.0–74.9 8.0–10.0
3 1.0–1.9 25.0–49.9 6.5–7.9
4 o1.0 o25.0 o6.5
Table 7 Maximum grade of white blood cell toxicity
CHOP
(n¼168)
PMitCEBO
(n¼172)
CHOP+GCSF
(n¼172)
PMitCEBO
+GCSF (n¼169)
Total
(n¼681)
%% % % %
White blood cell toxicity
0 32 6 33 30 25
1 15 5 15 7 11
21 2 1 9 1 5 1 4 1 5
31 8 4 0 1 5 2 2 2 4
42 3 3 1 2 2 2 7 2 6
Definitions of white blood cell toxicity
Grade WBC (10
9/l)
0 X4.0
1 3.0–3.9
2 2.0–2.9
3 1.0–1.9
4 o1.0
Table 8 In-patient days
CHOP PMitCEBO
CHOP
+GCSF
PMitCEBO
+GCSF Total
In-patient days %%%% %
0 4 24 64 54 6 4 5
1 – 5 1 21 61 82 1 1 7
6–10 12 11 8 9 10
1 1 – 2 0 1 0798 9
2 1 – 3 0 5643 4
43 0 9686 7
Missing data 11 8 7 8 8
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received PMitCEBO, as this regimen was associated with more
leucopenia. The proportion of patients treated with PMitCEBO
without G-CSF who developed grade 3 or 4 leucopenia during
treatment was 70% compared to 50% in those who received G-CSF
(Table 7). There was no difference in infection toxicity or days in
hospital (P¼0.95) between the two groups.
DISCUSSION
Special consideration of the management of elderly patients with
aggressive NHL is necessary because of the increased risk of
toxicity, morbidity and mortality from treatment and disease in
this patient population. CHOP has been the most widely used
regimen but treatment in the elderly is unsatisfactory, particularly
when it is considered that many patients with co-morbidity, never
receive such intensive combination chemotherapy regimens
(Janssen-Heijnen et al, 2005). It is essential that regimens intended
to reduce toxicity do not have a major negative impact on disease-
response and this requires large trials, which have rarely been
carried out in the elderly population. For this reason, the target
recruitment for this trial was 880 patients and although the trial
had to be terminated early, 89% of recruitment had occurred.
Furthermore, the estimation of numbers required was based on an
anticipated FFS at 3 years of 30% with the CHOP only regimen. In
fact, the 3-year FFS in this arm was 44% and to see a 10% change
from this baseline requires fewer patients, thus increasing the
robustness of the results obtained.
The results of this trial are in accord with the poorer prognosis
of older patients, but they also reaffirm that many elderly patients
with histologically aggressive NHL can be cured of their disease.
The 3-year overall survival for all patients of 46% compares
favourably with other studies despite the high upper age-limit
and the fact that over 50% of patients had poor prognostic
disease as defined by the IPI (Osby et al, 2003; Pfreundschuh et al,
2004b; Feugier et al, 2005). Every effort should therefore be
made to administer anthracycline-containing combination chemo-
therapy to elderly patients, if co-morbidity allows. Although
outcome was worse in patients X70 years, the overall survival at 3
years was over 35% justifying treatment with curative intent,
although of course, increasing patient selection is inevitable
with the older patients. The worst prognosis patient group, that
is, X70 years and IPI score 2–3, still achieved a 3 year overall
survival of 28%.
This trial has demonstrated almost identical FFS and OS with
CHOP and PMitCEBO. This equivalence of survival is despite the
fact that the CR rate was less with PMitCEBO and presumably
reflects that the earlier response assessment carried out with the
shorter duration regimen underestimates the true response rate
because of residual necrotic or fibrotic tissue (Surbone et al,
1988; Sweetenham et al, 1991). PMitCEBO is thus a valid
alternative to CHOP contrasting with several other curtailed or
modified regimens, which appear to be inferior (Meyer et al, 1995;
Sonneveld et al, 1995; Bastion et al, 1997; Tirelli et al, 1998; Osby
et al, 2003). A decision as to whether to use CHOP or PMitCEBO
should therefore be based on the ease of administration and the
comparative toxicities of the two regimens. PMitCEBO is given
over a shorter treatment duration, although the number of hospital
visits for injection of cytotoxic drugs is actually greater. PMitCEBO
also induces less alopecia and less gastrointestinal disturbance. In
addition, there is a reduced anthracycline dose with PMitCEBO.
Assuming that 1mgm
 2 mitoxantrone equates to 5mgm
 2
doxorubicin (Posner et al, 1985), PMitCEBO contains about 30%
less anthracycline than CHOP. This is potentially important in
elderly patients in whom the incidence of cardiac toxicity may be
higher than previously recognised and the threshold for damage
may be within the range of the amount of doxorubicin given with
CHOP (Swain et al, 2003).
The addition of prophylactic G-CSF to the two chemotherapy
regimens, particularly PMitCEBO, resulted in a reduction in
episodes of severe leucopenia in accord with previous studies
(Zinzani et al, 1997; Doorduijn et al, 2003; Osby et al, 2003). This
did not however impact on the rate of admission to hospital or
the duration of hospitalisation, which reflect the incidence and
severity of neutropenic sepsis. This concurs with the study of 389
patients reported by Doordujin et al, who found no impact of G-
CSF on the incidence of infections or time in hospital in elderly
patients receiving CHOP, although the studies by Osby and
Zinzani et al found less infections and fewer days in hospital
associated with G-CSF use. Most importantly, the use of G-CSF in
this study did not improve the response rates, FFS or OS
concordant with the studies referred to above. Taken together,
this supports the assertion that primary prophylaxis with G-CSF is
not indicated in elderly patients with NHL treated with regimens
such as CHOP, although G-CSF is clearly required if CHOP is
‘time-escalated’ with reduction of the interval between cycles to 2
weeks (Wunderlich et al, 2003). It may also be warranted in
selected individuals at particularly high risk for developing
neutropenic sepsis (Balducci et al, 2001).
Table 9 Causes of death
CHOP PMitCEBO CHOP+GCSF PMitCEBO+GCSF Total
Cause of death N % N % N % N % N %
NHL 87 77 84 80 71 71 76 76 318 76
Other malignancy 7 6 1 1 2 2 2 2 12 3
Death on treatment
Infection 4 4 5 5 2 2 1 1 12 3
Cardiac 5 4 2 2 2 2 7 7 16 4
Other 1 1 2 2 4 4 4 4 11 3
Unknown 0 0 0 0 0 0 0 0 0 0
Death after treatment
Infection 2 2 2 2 4 4 2 2 10 2
Cardiac 3 3 7 7 7 7 3 3 20 5
Other 1 1 2 2 3 3 5 5 11 3
Unknown 3 3 0 0 4 4 0 0 7 2
Total
a 113 100 105 100 99 100 100 100 417 100
aIn total, 419 patients died. For two patients, who died from infection, it is not clear from the data whether they died on or after treatment (one in CHOP arm, one in CHOP+G-
CSF arm).
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sThis trial was conducted before the advent of rituximab, and it
is now widely accepted that rituximab should be given with
chemotherapy in all cases of DLBC lymphoma (Pfreundschuh et al,
2004a; Feugier et al, 2005). This does not, however, detract from
the finding in this study that PMitCEBO is an acceptable
alternative to CHOP when the toxicity profile of PMitCEBO is
preferable or more appropriate to the individual patient. The use
of rituximab in addition to CHOP is associated with a marginal
increase in neutropenia but not sufficient to affect the incidence of
neutropenic fever or bacterial infections (Feugier et al, 2005). It is
very unlikely, therefore, that the lack of clinical benefit found in
this study with G-CSF use would be different with a rituximab
containing regimen.
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